Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association

Craig J. Beavers, Jo E. Rodgers, Aaron J. Bagnola, Theresa M. Beckie, Umberto Campia, Katherine E. Di Palo, Tochi M. Okwuosa, Eugene R. Przespolewski, Susan Dent

Research output: Contribution to journalReview articlepeer-review

40 Scopus citations


In the cardio-oncology population, drug interactions are of particular importance given the complex pharmacological profile, narrow therapeutic index, and inherent risk of therapies used to manage cardiovascular disease and cancer. Drug interactions may be beneficial or detrimental to the desired therapeutic effect. Clinicians in both cardiology and oncology should be cognizant of these potential drug-drug interactions that may reduce the efficacy or safety of either cardiovascular or cancer therapies. These risks can be mitigated through increased recognition of potential drug-drug interaction, use of alternative medications when possible, and careful monitoring. This scientific statement provides clinicians with an overview of pharmacodynamic and pharmacokinetic drug-drug interactions in patients with cancer exposed to common cardiovascular and cancer medications.

Original languageEnglish (US)
Pages (from-to)E811-E838
Issue number15
StatePublished - Apr 12 2022


  • AHA Scientific Statements
  • cardiovascular system
  • drug interactions
  • medical oncology
  • pharmacokinetics
  • pharmacology

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)


Dive into the research topics of 'Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association'. Together they form a unique fingerprint.

Cite this